Abstract
Directly Observed Therapy Strategy (DOTS) -Plus is a part of DOTS program that adds approach for multidrug resistance tuberculosis (MDR-TB) diagnosis, management, and treatment. WHO approved DOTS-Plus program began in 2000 and was established to encourage access to high quality second line drugs for appropriate use in MDR-TB control programs. The top priority is to prevent the emergence of MDR-TB by ensuring a low default rate of cases treated with first-line anti-TB drugs. If MDR-TB has emerged in a certain area, it should be treated in addition to improving the basic treatment. In this situation, accurate and reliable drug susceptibility testing, methods to support patients in order to ensure direct observation of complete treatment and the use of maximally effective regimens must be ensured. Second-line drugs should not be held back in patients with MDR-TB rather they have a good chance of cure with it, hence the treatment, if it is to be provided, should be optimally selected and administered. This review is highlighting the pharmacological view point of second line anti tubercular drug incorporated in DOTS-Plus therapy for MDR-TB.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
